BIIB vs RVMD stock comparison
Biogen vs. Revolution Medicines · data as of November 13, 2026
Biogen (BIIB) has a market value of about $37.5B, Revolution Medicines (RVMD) about $37.3B. Over their latest twelve months Biogen had revenue of $10.3B and Revolution Medicines $198M.
On our five checks Biogen scores higher: 1.8 out of 5 (weak) against 0.6 (weak).
By area, the stronger company is Biogen on value; Biogen on future growth; Biogen on track record; Biogen on financial health; Biogen on shareholder returns.
Biogen leads on 12 of the compared lines and Revolution Medicines on 1.
Side by side
| BIIB | RVMD | |
|---|---|---|
| Size and price | ||
| Market cap | $37.5B | $37.3B |
| Share price | $253.40 | $172.29 |
| Score | ||
| Overall score (of 5) | 1.8 | 0.6 |
| Value | 1 | 0 |
| Future growth | 2 | 1 |
| Track record | 1 | 0 |
| Financial health | 4 | 2 |
| Shareholder returns | 1 | 0 |
| Valuation | ||
| P/E (TTM) | 109.2 | — |
| Forward P/E | 17.4 | — |
| Price / free cash flow | 18.1 | — |
| Price / sales | 3.6 | 188.6 |
| EV / EBITDA | 26.7 | — |
| PEG | — | — |
| DCF value vs. price | −33% | — |
| Business | ||
| Revenue | $10.3B | $198M |
| Net income | $348M | -$1.9B |
| Free cash flow | $2.1B | -$1.4B |
| Net margin | 3.4% | -946.8% |
| Gross margin (5-yr avg.) | 76.9% | — |
| ROIC (5-yr avg.) | 9.2% | -36.5% |
| Growth | ||
| Revenue growth (1 yr) | 2.2% | — |
| Revenue growth (5 yrs, per year) | -6.0% | -100.0% |
| EPS growth (5 yrs, per year) | -18.7% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$6.1B | — |
| Dividend yield | None | None |
| Shareholder yield | 0.0% | 0.0% |
| Analysts | ||
| Upside to average target | +6% | +59% |
| Consensus rating | Buy | Strong buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: BIIB TTM to September 30, 2026, RVMD TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Biogen or Revolution Medicines?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Biogen scores 1.8 out of 5 and Revolution Medicines 0.6; the table shows where each one is stronger.
Which grows faster, Biogen or Revolution Medicines?
Over five years Biogen grew revenue about -6.0% a year and Revolution Medicines about -100.0% a year.
Full Biogen analysis → Full Revolution Medicines analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.